These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31502253)

  • 1. Drug-Placebo Additivity in Randomized Clinical Trials.
    Hall KT; Loscalzo J
    Clin Pharmacol Ther; 2019 Dec; 106(6):1191-1197. PubMed ID: 31502253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can knowledge of Placebo and Nocebo Mechanisms Help Improve Randomized Clinical Trials?
    Carlino E; Vase L
    Int Rev Neurobiol; 2018; 138():329-357. PubMed ID: 29681333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot seminar on ethical issues in clinical trials for cancer researchers in Vietnam.
    Love RR; Fost N
    IRB; 2003; 25(6):8-10. PubMed ID: 15035249
    [No Abstract]   [Full Text] [Related]  

  • 4. Placebo and Active Treatment Additivity in Placebo Analgesia: Research to Date and Future Directions.
    Coleshill MJ; Sharpe L; Colloca L; Zachariae R; Colagiuri B
    Int Rev Neurobiol; 2018; 139():407-441. PubMed ID: 30146056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are placebo-controlled studies required in order to prove efficacy of antidepressants?
    Möller HJ
    World J Biol Psychiatry; 2005; 6(3):130-1. PubMed ID: 16166027
    [No Abstract]   [Full Text] [Related]  

  • 6. Are placebo and drug-specific effects additive? Questioning basic assumptions of double-blinded randomized clinical trials and presenting novel study designs.
    Kube T; Rief W
    Drug Discov Today; 2017 Apr; 22(4):729-735. PubMed ID: 27919806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active placebo control groups of pharmacological interventions were rarely used but merited serious consideration: a methodological overview.
    Jensen JS; Bielefeldt AØ; Hróbjartsson A
    J Clin Epidemiol; 2017 Jul; 87():35-46. PubMed ID: 28342907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can placebo controls reduce the number of nonresponders in clinical trials? A power-analytic perspective.
    Leon AC
    Clin Ther; 2001 Apr; 23(4):596-603. PubMed ID: 11354393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Placebo response: in studies on pain and under other clinical conditions].
    Weimer K; Horing B; Klosterhalfen S; Enck P
    Schmerz; 2011 Jun; 25(3):325-35. PubMed ID: 21692009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics and the placebo effect: the placebome.
    Hall KT; Loscalzo J; Kaptchuk TJ
    Trends Mol Med; 2015 May; 21(5):285-94. PubMed ID: 25883069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo protects subjects from nonresponse: a paradox of power.
    Leon AC
    Arch Gen Psychiatry; 2000 Apr; 57(4):329-30. PubMed ID: 10768693
    [No Abstract]   [Full Text] [Related]  

  • 12. The mousetrap: managing the placebo effect in antidepressant trials.
    Lakoff A
    Mol Interv; 2002 Apr; 2(2):72-6. PubMed ID: 14993352
    [No Abstract]   [Full Text] [Related]  

  • 13. Select-drop designs in clinical trials.
    Ellenberg SS
    Am Heart J; 2000 Apr; 139(4):S158-60. PubMed ID: 10740123
    [No Abstract]   [Full Text] [Related]  

  • 14. Historical Controls in Randomized Clinical Trials: Opportunities and Challenges.
    Hall KT; Vase L; Tobias DK; Dashti HT; Vollert J; Kaptchuk TJ; Cook NR
    Clin Pharmacol Ther; 2021 Feb; 109(2):343-351. PubMed ID: 32602555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons to be learned from placebo arms in psychopharmacology trials.
    Doering BK; Rief W; Petrie KJ
    Handb Exp Pharmacol; 2014; 225():273-90. PubMed ID: 25304537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N of 1 randomized trials for investigating new drugs.
    Guyatt GH; Heyting A; Jaeschke R; Keller J; Adachi JD; Roberts RS
    Control Clin Trials; 1990 Apr; 11(2):88-100. PubMed ID: 2161315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do we need a new procedure for the assessment of adverse events in anti-migraine clinical trials?
    Amanzio M
    Recent Pat CNS Drug Discov; 2011 Jan; 6(1):41-7. PubMed ID: 21118096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Placebo Response Responsible for Many Phase III Failures?
    Dumitrescu TP; McCune J; Schmith V
    Clin Pharmacol Ther; 2019 Dec; 106(6):1151-1154. PubMed ID: 31713241
    [No Abstract]   [Full Text] [Related]  

  • 20. Placebo response and antidepressant clinical trial outcome.
    Khan A; Detke M; Khan SR; Mallinckrodt C
    J Nerv Ment Dis; 2003 Apr; 191(4):211-8. PubMed ID: 12695731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.